ArticleGut microbes2026
Early-life gut dysbiosis programs divergent metabolic trajectories in a sex-dependent manner.
Article in Gut microbes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous studies have established that long-term antibiotic (ABX) exposure disrupts gut microbiota, leading to adiposity, insulin resistance, and metabolic dysfunction-associated steatotic liver disease (MASLD). However, the metabolic effects of short-term ABX treatment in early life, along with the underlying mechanism, remain unclear. This study reveals that short-term ABX exposure during early life induces sex-specific metabolic programming in mice. Immature males exhibited reduced gonadal white adipose tissue (gWAT) mass, predisposing them to exacerbated hepatic steatosis under high-fat diet (HFD) challenge. Females displayed protected liver metabolism. We identified dimethylarsinous acid (DMAIII) as a key microbiota-dependent metabolite that inversely correlated with both gWAT mass and specific bacterial abundances, including
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.